A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal ...

Gastric cancer (GC) is a leading cause of cancer-related deaths worldwide, with more than one million new diagnoses annually.

Company has one year of cash to fund operations Company advancing plans to develop TPI 287, a novel, late stage abeotaxane ...

Oral and poster presentations of its DZD8586 study results in chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL) are selected by ASCO Scientific Program Committee. In ...

Nuvalent, Inc. (NASDAQ:NUVL – Get Free Report) has been assigned an average rating of “Moderate Buy” from the eleven ratings ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

Seven-year follow-up data of a multicenter, randomized phase 2 study evaluating the treatment of melanoma brain metastases shows ipilimumab plus nivolumab is an effective long-term care option. First ...

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy. Lerociclib plus fulvestrant demonstrated a ...

Experts discuss how, nearly half of patients diagnoses with HER-2 positive metastatic brain cancer do develop brain metastasis. It is thought that larger molecule treatments such as the monoclonal ant ...

Teacher Retirement System of Texas lifted its stake in shares of Nuvalent, Inc. (NASDAQ:NUVL – Free Report) by 43.1% during the fourth quarter, according to its most recent disclosure with the ...

January 2023 changed Sandra Manro's life. "I have stage four metastatic breast cancer that metastasized in my spine and brain," said Manro. "We found it because I fell and I had a fracture." Manro's ...

The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive ...